SEC Form 4 · accession 0000899243-15-010547
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip M Nudelman Ph.D.
Director
Period of report
Dec 29, 2015
Accepted (ET)
Dec 31, 2015 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.27 | Dec 29, 2015 | A | 100,000 | A | — | Dec 28, 2025 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1This stock option was granted on December 29, 2015 and vests on the date that is six months after the date of grant or, if earlier, the first annual meeting of CTIC's shareholders in 2016 at which one or more members of the CTIC Board of Directors are to be elected.